Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of painful days · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of painful days compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in frequency of oral ulcers compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Episode frequency associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
SoF (topical interventions vs placebo), grouped comment spanning all four listed outcomes (verbatim): "5 placebo-controlled trials evaluated topical interventions (sucralfate suspension (2 trials), interferon-alpha (2…
Studies not reported
GRADE not reported
Intervention not reported
Sucralfate versus nonadherent · people with venous leg ulcers
The intervention may leads to higher sucralfate versus nonadherent (low certainty).
1 finding from 1 review
RR 6.8 [2.24, 20.7]
Studies not reported
Low
Intervention not reported
Sucralfate versus foam · people with venous leg ulcers
The intervention may leads to higher sucralfate versus foam (low certainty).
1 finding from 1 review
RR 5.94 [1.96, 18]
Studies not reported
Low
Intervention not reported
Sucralfate versus hydrocolloid · people with venous leg ulcers
The intervention may leads to higher sucralfate versus hydrocolloid (low certainty).
1 finding from 1 review
RR 6.51 [2.17, 19.6]
Studies not reported
Low
Intervention not reported
Sucralfate versus silver · people with venous leg ulcers
It is very uncertain whether the intervention changes sucralfate versus silver (very low certainty).
1 finding from 1 review
RR 2.8 [0.88, 8.97]
Studies not reported
Very low
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in clinically important upper GI bleeding compared with sucralfate (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists probably leads to higher nosocomial pneumonia compared with sucralfate (moderate certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review
Duration of ICU stay · people admitted to intensive care units
1 finding from 1 review
Blood transfusion · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in number of participants requiring blood transfusion compared with sucralfate (low certainty).
1 finding from 1 review
Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
Antacids showed no clear difference in clinically important upper GI bleeding compared with sucralfate (low certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
Antacids showed no clear difference in nosocomial pneumonia compared with sucralfate (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
Antacids showed no clear difference in all‐cause mortality in ICU compared with sucralfate (low certainty).
1 finding from 1 review